Nextleaf Solutions Ltd (CSE:OILS) (OTCQB:OILFF) announced Wednesday that the Canadian Intellectual Property Office has granted the company a patent covering the creation of a THC prodrug, its 40th issued patent.
Specifically, the patent describes a process for acetylating (inserting an acetyl group into a compound) delta 9-tetrahydrocannabinol (THC) and refining it into THC-O-Acetate using salting-out assisted liquid-liquid extraction and distillation techniques.
THC-O-Acetate is prodrug, which can enhance the potency of THC.
READ: Nextleaf Solutions commercializing its intellectual property and scaling up biomass processing
"Nextleaf's patented process to produce THC-O-Acetate enables the standardization of a more potent analog of THC, an alternative option to experience the unique medicinal benefits, associated with targeted drug delivery," CEO Paul Pedersen said in a statement. "The potency of THC-O-Acetate is said to be 300% that of THC with potentially psychedelic features."
Nextleaf’s goal is to maintain the integrity of the molecule and its ability to deliver drugs to precisely targeted areas in order to significantly reduce consumption, as well as reduce unintended side effects.
"To the best of my knowledge, Nextleaf is the first company in the world, publicly traded or private, to be issued patents for the production of THC-O-Acetate in any jurisdiction, including the United States and Canada," Director of Intellectual Property Taran Grey said.
Nextleaf said it has a 100% success rate obtaining issued patents from its pending patent applications, compared to averages below 50% for life sciences companies. The Vancouver-based company expects opportunities to commercialize its latest patent through IP licensing agreements with pharmaceutical companies and by producing IP-protected cannabinoid products.
Contact Andrew Kessel at email@example.com
Follow him on Twitter @andrew_kessel